Cargando…

Favorable Immune Microenvironment in Patients with EGFR and MAPK Co-Mutations

PURPOSE: Although EGFR-mutated patients generally do not benefit from checkpoint inhibitors (ICIs), some patients in the KEYNOTE-001 study consistently benefited from this treatment. This study investigated immune microenvironment characteristics to identify the subgroup of patients that may benefit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Wang, Chen, Naifei, Li, Lingyu, Chen, Xiao, Liu, Xiangliang, Zhang, Yongfei, Cui, Jiuwei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7490071/ https://www.ncbi.nlm.nih.gov/pubmed/32982525 http://dx.doi.org/10.2147/LCTT.S262822

Ejemplares similares

Efficacy and Safety of Epidermal Growth Factor Receptor (EGFR) Inhibitors Plus Antiangiogenic Agents as First-Line Treatments for Patients With Advanced EGFR-Mutated Non-small Cell Lung Cancer: A Meta-Analysis
por: Chen, Fei, et al.
Publicado: (2020)

Nerves in the Tumor Microenvironment: Origin and Effects
por: Wang, Wenjun, et al.
Publicado: (2020)

Correlation of Peripheral Blood Parameters and Immune-Related Adverse Events with the Efficacy of Immune Checkpoint Inhibitors
por: Bai, Rilan, et al.
Publicado: (2021)

Analysis of characteristics and predictive factors of immune checkpoint inhibitor-related adverse events
por: Bai, Rilan, et al.
Publicado: (2021)

Friend leukemia virus integration 1 is a predictor of poor prognosis of breast cancer and promotes metastasis and cancer stem cell properties of breast cancer cells
por: Yan, Xu, et al.
Publicado: (2018)

Efficacy of second-line treatments for patients with advanced human epidermal growth factor receptor 2 positive breast cancer after trastuzumab-based treatment: a systematic review and bayesian network analysis
por: Chen, Fei, et al.
Publicado: (2021)

Neoadjuvant and Adjuvant Immunotherapy: Opening New Horizons for Patients With Early-Stage Non-small Cell Lung Cancer
por: Bai, Rilan, et al.
Publicado: (2020)

A Neutrophil Extracellular Traps Signature Predicts the Clinical Outcomes and Immunotherapy Response in Head and Neck Squamous Cell Carcinoma
por: Chen, Naifei, et al.
Publicado: (2022)

Novel Frontiers of Treatment for Advanced Gastric or Gastroesophageal Junction Cancer (GC/GEJC): Will Immunotherapy Be a Future Direction?
por: Bai, Rilan, et al.
Publicado: (2020)

Mechanisms of Cancer Resistance to Immunotherapy
por: Bai, Rilan, et al.
Publicado: (2020)

Direct oral anticoagulants versus low molecular weight heparins for the treatment of cancer-associated thrombosis: a cost-effectiveness analysis
por: Wumaier, Kaidireyahan, et al.
Publicado: (2021)

The immune microenvironment in EGFR- and ERBB2-mutated lung adenocarcinoma
por: Kirchner, M., et al.
Publicado: (2021)

Comprehensive Comparison Between Adjuvant Targeted Therapy and Chemotherapy for EGFR-Mutant NSCLC Patients: A Cost-Effectiveness Analysis
por: Li, Wenqian, et al.
Publicado: (2021)

Precision targeted therapy for EGFR mutation‐positive NSCLC: Dilemmas and coping strategies
por: Meng, Ying, et al.
Publicado: (2023)

Anaplastic lymphoma kinase-special immunity and immunotherapy
por: Guo, Ye, et al.
Publicado: (2022)

Emerging Role of EGFR Mutations in Creating an Immune Suppressive Tumour Microenvironment
por: Kapoor, Simran S., et al.
Publicado: (2021)

The correlation between skeletal muscle index of the L3 vertebral body and malnutrition in patients with advanced lung cancer
por: Liu, Xiangliang, et al.
Publicado: (2021)

Clinical Progress of PD-1/L1 Inhibitors in Breast Cancer Immunotherapy
por: Chen, Fei, et al.
Publicado: (2022)

High mutation load, immune-activated microenvironment, favorable outcome, and better immunotherapeutic efficacy in melanoma patients harboring MUC16/CA125 mutations
por: Wang, Qinghua, et al.
Publicado: (2020)

Antimetabolite pemetrexed primes a favorable tumor microenvironment for immune checkpoint blockade therapy
por: Lu, Chia-Sing, et al.
Publicado: (2020)

CD38 Predicts Favorable Prognosis by Enhancing Immune Infiltration and Antitumor Immunity in the Epithelial Ovarian Cancer Microenvironment
por: Zhu, Ying, et al.
Publicado: (2020)

Targeted therapy combined with immunotherapy in patients with breast infiltrating ductal carcinoma with axillary lymph node metastasis of metaplastic SCC
por: Bai, Rilan, et al.
Publicado: (2022)

Biofunctionalized composite scaffold to potentiate osteoconduction, angiogenesis, and favorable metabolic microenvironment for osteonecrosis therapy
por: Zhu, Tongtong, et al.
Publicado: (2021)

Co-mutations in tumor immune microenvironment and immunotherapy
por: Ma, Ling, et al.
Publicado: (2021)

Domatinostat favors the immunotherapy response by modulating the tumor immune microenvironment (TIME)
por: Bretz, Anne Catherine, et al.
Publicado: (2019)

MAPK pathway mutations in head and neck cancer affect immune microenvironments and ErbB3 signaling
por: Ngan, Hoi-Lam, et al.
Publicado: (2020)

Spred-3 mutation and Ras/Raf/MAPK activation confer acquired resistance to EGFR tyrosine kinase inhibitor in an EGFR mutated NSCLC cell line
por: He, Zhiyong, et al.
Publicado: (2020)

Advanced pancreatic cancer with KRAS wild-type and EGFR-sensitive mutation respond favorably to furmonertinib: A case report
por: Ma, Xiaoting, et al.
Publicado: (2023)

Development of Immunotherapy Strategies Targeting Tumor Microenvironment Is Fiercely Ongoing
por: Bai, Rilan, et al.
Publicado: (2022)

Breast cancers with EGFR and HER2 co-amplification favor distant metastasis and poor clinical outcome
por: Guo, Peng, et al.
Publicado: (2017)

Heterogeneity of tumor immune microenvironment of EGFR/ALK-positive tumors versus EGFR/ALK-negative tumors in resected brain metastases from lung adenocarcinoma
por: Xiao, Gang, et al.
Publicado: (2023)

Single Nucleotide Polymorphisms in HOTAIR Are Related to Breast Cancer Risk and Prognosis in the Northeastern Chinese Population
por: Lv, Zheng, et al.
Publicado: (2021)

Divergent EGFR/MAPK-Mediated Immune Responses to Clinical Candida Pathogens in Vulvovaginal Candidiasis
por: Zhang, Jingyun, et al.
Publicado: (2022)

Circadian disruption promotes tumor-immune microenvironment remodeling favoring tumor cell proliferation
por: Aiello, I., et al.
Publicado: (2020)

Single-cell transcriptome analysis revealed a suppressive tumor immune microenvironment in EGFR mutant lung adenocarcinoma
por: Yang, Lei, et al.
Publicado: (2022)

BHLHE22 Expression Is Associated with a Proinflammatory Immune Microenvironment and Confers a Favorable Prognosis in Endometrial Cancer
por: Darmawi,, et al.
Publicado: (2022)

Prognostic value of MICA/B in cancers: a systematic review and meta-analysis
por: Zhao, Yijing, et al.
Publicado: (2017)

CMTM6 and PD-L1 coexpression is associated with an active immune microenvironment and a favorable prognosis in colorectal cancer
por: Peng, Qi-Hua, et al.
Publicado: (2021)

Ablative Radiotherapy Reprograms the Tumor Microenvironment of a Pancreatic Tumor in Favoring the Immune Checkpoint Blockade Therapy
por: Lee, Yu-Hung, et al.
Publicado: (2021)

Advances and challenges in immunotherapy of small cell lung cancer
por: Guo, Hanfei, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_2p70u5n26k98o5surtqup9ue52